



**Resolution (Number 2025-1) Addressing Shared Governance and Transparency Concerns with the Office of Research and Sponsored Programs (ORSP)
University of Toledo College of Medicine and Life Sciences (UToledo COMLS)**

- WHEREAS** the University of Toledo College of Medicine and Life Sciences (UToledo COMLS) is a distinguished institution committed to excellence in medical education, innovative research, and exceptional patient care;
- WHEREAS** under the current operations of ORSP, the COMLS faculty have experienced 1) substantial delays in clinical trial reviews, thereby endangering critical research projects and limiting COMLS's ability to compete even with local medical centers; 2) severe declines in clinical research studies and associated revenue from \$2.1 million in FY20 to \$434,603 in FY24 (see appendix)
- WHEREAS** faculty and staff at COMLS have reported dissatisfaction with the performance of ORSP, citing inadequate support, lack of responsiveness including the absence of a dedicated UToledo Health Science Campus Institutional Review Board (IRB) and clinical contract reviewers on the Health Science Campus repeated training demands, and administrative errors; (see appendix)
- WHEREAS** the ORSP leadership has not communicated to COMLS Faculty a plan to address the precipitous decline in research productivity and overall dissatisfaction with the operations of ORSP
- WHEREAS** these issues jeopardize faculty careers, the research and educational mission of COMLS, and its reputation as a nationally recognized research institution;

NOW, THEREFORE, BE IT RESOLVED that the UToledo COMLS Faculty calls on university leadership to:


1. Develop an immediate action plan with COMLS faculty leadership to address the ongoing issues outline above including providing COMLS with the resources and autonomy required to manage its own research operations effectively to restore its competitive edge in clinical research.

Adopted this 28 day of February 2025, by the Faculty Council of the University of Toledo College of Medicine and Life Sciences.

Appendix.


Sponsored Clinical Trials						
FY	Arts and Letters	Medical Services	Medicine & Life Sci	Nursing	Pharm & Pharm Sci	Total
2020	1	1	79	1	1	83
2021	1	1	71		1	74
2022			59			59
2023			34		1	35
2024			20			20
2025*			9			9
FY	Arts and Letters	Medical Services	Medicine & Life Sci	Nursing	Pharm & Pharm Sci	Total
2020	\$18,557	\$26,543	\$2,181,143	\$59,132	\$0	\$2,285,375
2021	\$21,460	\$22,276	\$1,927,081		\$16,176	\$1,986,993
2022			\$1,549,082			\$1,549,082
2023			\$1,232,118		\$10,055	\$1,242,173
2024			\$434,608			\$434,608
2025*			\$152,102			\$152,102
FY	Corporate	Federal	Foreign Industry	Non-Profit	Total	
2020	\$1,180,536	\$14,728	\$792,793	\$297,318	\$2,285,375	
2021	\$1,079,132	\$283,000	\$595,210	\$29,650	\$1,986,993	
2022	\$1,325,843	\$26,868	\$196,370		\$1,549,082	
2023	\$1,099,226	\$24,000	\$118,947		\$1,242,173	
2024	\$317,072	\$16,000	\$101,537		\$434,609	
2025*	\$128,515		\$23,588		\$152,103	
FY	Corporate	Federal	Foreign Industry	Non-Profit	Total	
2020	51	2	26	4	83	
2021	44	3	23	4	74	
2022	38	3	18		59	
2023	26	1	8		35	
2024	13	1	6		20	
2025*	5		4		9	
Indirect Cost Recovery (IDCR) for sponsored clinical research by FY						
FY	2017	2018	2019	2020	2021	2022
IDCR	446,879	498,119	275,905	543,631	558,805	360,047
						350,437

Are you actively involved in research?



Answer	Count	Percent	20%	40%	60%	80%	100%
Yes, very actively.	46	48.42%	<div></div>				
Yes, somewhat actively.	24	25.26%	<div></div>				
Occasionally involved.	14	14.74%	<div></div>				
No, I'm not currently involved in research.	11	11.58%	<div></div>				
Total	95	100 %					

Are you satisfied with our research study approval process?



Answer	Count	Percent	20%	40%	60%	80%	100%
Very satisfied.	5	7.25%	<div></div>				
Somewhat satisfied.	18	26.09%	<div></div>				
Somewhat dissatisfied.	21	30.43%	<div></div>				
Very dissatisfied.	25	36.23%	<div></div>				
Total	69	100 %					